Last reviewed · How we verify
Lipanthyl
Lipanthyl is a Small molecule drug developed by Hoda A. Atta. It is currently in Phase 2 development. Also known as: ursogal.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lipanthyl |
|---|---|
| Also known as | ursogal |
| Sponsor | Hoda A. Atta |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (PHASE2)
- A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes (PHASE2)
- The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. (PHASE3)
- Fenofibrate in Primary Biliary Cholangitis: a Real World Study (PHASE3)
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis (PHASE2, PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study (PHASE3)
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipanthyl CI brief — competitive landscape report
- Lipanthyl updates RSS · CI watch RSS
- Hoda A. Atta portfolio CI
Frequently asked questions about Lipanthyl
What is Lipanthyl?
Who makes Lipanthyl?
Is Lipanthyl also known as anything else?
What development phase is Lipanthyl in?
Related
- Manufacturer: Hoda A. Atta — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: ursogal
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing